University College Cardiff Consultants Limited 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271. [Patent]. |
Preview |
PDF
- Published Version
Download (14MB) | Preview |
Official URL: https://patentscope.wipo.int/search/en/detail.jsf?...
Abstract
The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAA receptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAA receptors, including depression and cognitive impairment, for example, cognitive impairment associated with a psychotic disorders such as schizophrenia.
Item Type: | Patent |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Biosciences |
Date of First Compliant Deposit: | 3 May 2024 |
Last Modified: | 06 Jun 2024 08:47 |
URI: | https://orca.cardiff.ac.uk/id/eprint/168702 |
Actions (repository staff only)
![]() |
Edit Item |